Y-mAbs Therapeutics Files 8-K
| Field | Detail |
|---|---|
| Company | Y-Mabs Therapeutics, Inc. |
| Form Type | 8-K |
| Filed Date | May 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, financials
TL;DR
Y-mAbs filed an 8-K, likely containing financial updates and other disclosures. Keep an eye out for details.
AI Summary
On May 28, 2025, Y-mAbs Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates that Y-mAbs Therapeutics, Inc. is providing updates or disclosures to the SEC, which could contain important information for investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and the provided excerpt does not contain specific negative news or significant financial changes.
Key Players & Entities
- Y-mAbs Therapeutics, Inc. (company) — Registrant
- 20250528 (date) — Filing Date
- 0001722964 (company) — Central Index Key
- 202 Carnegie Center Suite 301 Princeton, New Jersey 08540 (address) — Principal Executive Offices
FAQ
What specific 'Other Events' are being reported by Y-mAbs Therapeutics, Inc. in this 8-K filing?
The provided excerpt of the 8-K filing does not specify the details of the 'Other Events' being reported.
Are there any new financial statements included with this 8-K filing?
Yes, the filing indicates that 'Financial Statements and Exhibits' are included as part of the 8-K report.
What is the primary purpose of this 8-K filing for Y-mAbs Therapeutics, Inc.?
The filing serves as a Current Report for Y-mAbs Therapeutics, Inc., covering Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
When was this 8-K filing submitted to the SEC?
The filing was submitted on May 28, 2025.
What is the principal executive office address for Y-mAbs Therapeutics, Inc.?
The principal executive offices are located at 202 Carnegie Center Suite 301, Princeton, New Jersey 08540.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 28, 2025 regarding Y-mAbs Therapeutics, Inc..